New Delhi: In a significant development in an ongoing pharmaceutical dispute, the Supreme Court of India has declined to interfere with an order of the Allahabad High Court in a case involving Jamp ...

A fully-featured, console-based Cab Booking System built in Java that demonstrates 15 core Object-Oriented Programming concepts through a real-world ride-hailing simulation. The system covers ...

Following the March 20, 2026 patent expiry of semaglutide, India is witnessing a rapid influx of generic GLP-1 receptor agonists. This shift is reshaping market dynamics, with evolving regulatory ...

In India, China and other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In a shot in the arm for India’s high-growth weight-loss drugs market, generic versions of Danish drugmaker Novo Nordisk’s blockbuster drug semaglutide hit the shelves on Saturday, with price ...

In a shot in the arm for India’s high-growth weight-loss medicines market, generic versions of Danish drugmaker Novo Nordisk’s blockbuster drug semaglutide will hit the shelves on Saturday, with price ...

All the Indian generics are substantially cheaper – the prices vary between Rs 1,300 and Rs 4,500 per month - than the original ones.

With nearly 50 brands of generic semaglutide set to launch in the Indian market on Saturday, doctors applaud the reduced cost and increased availability of the drug for their patients, along with a ...

India’s obesity drug market is on the cusp of a shake-up, with at least a dozen large drugmakers preparing to launch generic versions of Novo Nordisk’s blockbuster weight-loss drugs as soon as patent ...

MUMBAI – A deluge of weight-loss drugs is set to transform the global fight against obesity, as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent ...

The global conversation around obesity and type 2 diabetes management has shifted dramatically in recent years, largely due to the rise of GLP-1 receptor compounds. Among them, semaglutide has emerged ...